Abstract ALG6-CDG (formerly named CDG-Ic) (phenotype OMIM 603147, genotype OMIM 604566), is caused by defective endoplasmic reticulum a-1,3-glucosyltransferase (E.C 2.4
Introduction
ALG6-CG (phenotype OMIM 603147, genotype OMIM 604566) is a genetic disorder in the assembly of N-glycans due to ER alpha-1,3-glucosyltransferase deficiency (E.C 2.4.1.267). It was first reported in 1998 (Burda et al. 1998; K€ orner et al. 1998 ) and about 37 patients have been described (Imbach et al. 1999 Gr€ unewald et al. 2000; Hanefeld et al. 2000; Westphal et al. 2000a Westphal et al. , b, 2003 de Lonlay et al. 2001; Schollen et al. 2002; Newell et al. 2003; Sun et al. 2005; Vuillaumier-Barrot 2005; Eklund et al. 2006; Haeuptle and Hennet 2009; Al-Owain et al. 2010) . The clinical presentation is mainly characterized by feeding problems and a moderately pronounced neurological disorder with psychomotor retardation, hypotonia, epilepsy, and internal strabismus Newell et al. 2003) . A minority of patients show other symptoms, particularly intestinal (such as protein-losing enteropathy (PLE)) and liver involvement (Damen et al. 2004) . Striking biochemical features are unusually low serum cholesterol; blood coagulation factor XI and anticoagulation factors antithrombin, protein C, and protein S; as well as variable hypoalbuminemia; low serum LDL-cholesterol; and endocrinological abnormalities (K€ orner et al. 1998; Gr€ unewald et al. 2000; Hanefield et al. 2000; Newell et al. 2003; Sun et al. 2005; Westphal et al. 2000a, b) . Table 1 summarizes clinical and molecular findings in ten ALG6-CDG patients reported since 1998. Twenty-one different mutations have been described but the majority of patients have the c.998C>T (p.A333V) mutation, either in a compound heterozygous or homozygous state (Imbach et al. 1999 Gr€ unewald et al. 2000; Hanefeld et al. 2000; Westphal et al. 2000a Westphal et al. , b, 2003 de Lonlay et al. 2001; Schollen et al. 2002; Newell et al. 2003; Sun et al. 2005; Vuillaumier-Barrot 2005; Eklund et al. 2006; Haeuptle and Hennet 2009; Al-Owain et al. 2010) . Haeuptle and Hennet (2009) reported that most of the mutations affect amino acids positioned within the 11 TM domains, which compromise the integrity of the protein structure and alter the properties responsible for the binding of dolichol-linked glycans.
Serum transferrin IEF profiles of ALG6-CDG patients show a type 1 CDG pattern. LLO (lipid-linked oligosaccharides) analysis of fibroblasts shows an accumulation of Man9GlcNAc2 (Imbach et al. 1999; Burda et al. 1998; Marklova and Albahri 2007) . A few isolated CDG-ALG6 patients (e.g., patients with the homozygous c.391TT>C, p.Y131H mutation) presented with a normal transferrin and LLO profile (Westphal et al. 2003; Miller et al. 2011) . The Laboratory for Inborn Errors of Metabolism started screening for CDG in 1998 and Du Plessis et al. (2001) reported on the first South African CDG patient. We report on five novel Caucasian patients from South Africa with previously described mutations and one novel mutation.
Patients and Methods

Patients
The ALG6 patients in this study formed part of the semiisolated Caucasian society, which can be defined as a population which is not found in a particular area in South Africa, but share the same historical past of forced segregation. These families may have originated from European pioneers who colonized South Africa in the seventeenth/eighteenth centuries, but further genealogy studies are needed in the future.
Patient 1 was referred to the Potchefstroom Newborn Screening (NBS) Laboratory in South Africa. A follow-up metabolic screen and CDG assays were suggested. Samples of patient 2, 3, 4, and 5 (Table 2) were initially referred to the Laboratory for Inborn Errors of Metabolism in Potchefstroom, South Africa, for a full metabolic investigation. The parents of the patients were all non-consanguineous and the patients were all Caucasian South Africans.
Patients 1, 2, and 3 had no family ties, but patients 4 and 5 were first cousins. The latter two patients were not related to patients 1, 2, and 3. Informed consent was given by the families for the CDG genotype studies and the group formed part of the EUROGLYCANET project.
Blood/Serum Transferrin IEF Transferrin IEF analysis was performed on blood cards, of all five patients in this study at the Laboratory for Inborn Errors of Metabolism in Potchefstroom, South Africa, according to the methodology of Du Plessis et al. (2001) . The validated blood card approach ensured a suitable sample for the transferrin analysis in a country, such as South Africa, in which transport and viability of samples could be compromised. Additional serum was collected from the five patients, who had a type 1 transferrin pattern on the blood card IEF analysis, and referred to the Academic Medical Centre (AMC), Amsterdam for confirmation.
ALG6 Mutation Analysis
Genomic DNA was isolated from EDTA blood of the patients, using the "NucleoSpin blood genomic DNA purification kit" (Macherey-Nagel, Germany, D€ uren). The ALG6 mutation analysis was performed by direct gene sequencing on DNA specimens, at the Department of Human Genetics of the University of Leuven Schollen et al. 2002) (The GenBank accession number of the ALG6 gene used in our study was NM_013339.3). An SNP database comparison and multiple alignment of the ALG6 protein were done for the novel mutation in this study.
Results
Clinical and Biochemical Description of Patients
Clinical data are summarized in Table 2 . Patient 1 had severe PLE and neurological involvement. The newborn screening (NBS) result of patient 1 was normal except for an abnormal IRT (immunoreactive trypsinogen) result
Cystic fibrosis was excluded and no other metabolic abnormalities were observed. A metabolic screening and CDG analysis were requested, after the patient presented with clinical deterioration.
Patients 2 to 5 did not undergo NBS. Specimens of patient 2, 3, and 5 were sent to the metabolic unit for full metabolic screening and a transferrin IEF CDG analysis was specifically requested from clinicians. A CDG analysis was performed on Blood/Serum Transferrin IEF All five patients showed a type 1 serum transferrin IEF profile, that was most pronounced in patient 1 (almost no tetrasialotransferrin) (Fig. 1 ).
ALG6 Mutational Analysis
Patient 1, with an intestinal-neurological phenotype, was found to be compound heterozygous for the c.998C>T (p.A333V) and c.1339dupA (p.V447SfsX44) mutations. Patient 2, 3, 4, and 5, with a predominantly neurological phenotype, were all compound heterozygous for the c.257 + 5G>A (originally described by Imbach et al. 2000 as the IVS3 + 5G!A mutation) and c.680G>A (p.G227E) mutations. The polymorphism, c.911C>T (p.S304F) was present in heterozygous state in patients 2, 3, 4, and 5. The carrier (father of patient 1) of the c.1339dupA (p.V447SfsX44) did not portray CDG-related symptoms.
The novel frameshift mutation, c.1339dupA (p.V447SfsX44), which we identified in this study, is not , and Tetraodon nigroviridis (pufferfish), indicated that the valine on position 447 is highly conserved. The frameshift mutation also results in the premature termination of the ALG6 protein (44 amino acids after the amino acid change) and therefore the formation of a truncated protein.
Discussion
The described patients showed two distinct phenotypes of ALG6-CDG deficiency. Patient 1 showed a severe, earlyonset, neuro-gastrointestinal presentation comparable with previously described case studies (Westphal et al. 2000b; Damen et al. 2004; Newell et al. 2003) . The patient was compound heterozygous for the prevalent c.998C>T (p.A333V) missense mutation (originally described by Imbach et al. 1999 ) and a novel c.1338dupA (p.V447SfsX44) frameshift mutation in the ALG6 gene. The p.A333V mutation is associated with a mild to moderate phenotype which indicates that the novel frameshift mutation (c.1338dupA), which results in the formation of a truncated ALG6 protein, probably explains the severe phenotype and early death of the patient as well as the unusually low serum tetrasialotransferrin. The phenotypic variation from the typical ALG6 deficiency concurs with previous literature of rare ALG6-CDG cases with multiple organ involvement and intestinal abnormality, e.g., PLE (Westphal et al. 2000b; Newell et al. 2003; Al-Owain et al. 2010) . Patients 2, 3, 4, and 5 presented with the classical ALG6-CDG phenotype comprising of a variable degree of neurological involvement, including hypotonia and resistant epilepsy. Other features in these patients were feeding problems, recurrent infections, and mild facial dysmorphism , Du Plessis et al. 2001 ). The c.257 + 5G>A splice site mutation (originally described by Imbach et al. 2000) in combination with the c.680G>A (p.G227E) missense mutation (originally described by Schollen et al. 2002) was identified in all four patients. The same combination of mutations in four patients may suggest that they have a common (most probably European) ancestor.
In summary, beside the patients with the classical neurological ALG6-CDG phenotype described in this study, we also identified an ALG6-CDG patient with an early onset of severe neurological and intestinal involvement associated with a novel frameshift mutation. This variation in ALG6 phenotype is in agreement with the literature summarized in Table 1 and suggests a genotypephenotype correlation. Aerschot from the Department of Human Genetics and the Centre for Metabolic Diseases, at the University of Leuven, for excellent technical assistance. We are grateful to the patients and their families as well as to the referral doctors for their participation and support in this study.
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